Annovis Bio Director Buys $1.5M in Shares

Insider purchase represents 27.72% increase in director's stake

Apr. 4, 2026 at 10:05am

Got story updates? Submit your updates here. ›

Annovis Bio, Inc. (NYSE:ANVS) Director Michael Hoffman acquired 713,800 shares of the company's stock in a transaction on Thursday, April 2nd. The shares were purchased at an average cost of $2.10 per share, with a total value of $1,498,980.00. Following the transaction, Hoffman now owns 3,288,539 shares in the company, valued at approximately $6,905,931.90.

Why it matters

Insider buying activity can be a positive signal for investors, as it suggests company leadership has confidence in the business's future prospects. Annovis Bio is a clinical-stage biotech focused on developing treatments for neurodegenerative diseases like Alzheimer's and Parkinson's.

The details

The transaction represented a 27.72% increase in Hoffman's stake in Annovis Bio. The company's stock trades near $2.28 with a market cap of about $64.5 million. In its most recent quarter, Annovis reported an EPS of -$0.39, missing analyst estimates. The stock carries a consensus 'Hold' rating with an average price target of $13.50.

  • The transaction occurred on Thursday, April 2nd, 2026.

The players

Michael Hoffman

Director of Annovis Bio, Inc.

Annovis Bio, Inc.

A clinical-stage biotech company focused on developing treatments for neurodegenerative diseases.

Got photos? Submit your photos here. ›

The takeaway

This insider buying activity suggests Annovis Bio's director has confidence in the company's pipeline and future prospects, despite the stock's recent performance missing analyst expectations. Investors will be watching to see if this purchase signals a potential turnaround for the biotech firm.